This post was originally published on this site Veru Healthcare has completed patient enrollment for its Phase 2 clinical trial evaluating the use of zuclomiphene citrate (VERU-944) for the treatment of hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are experienced by about 80% of men on androgen deprivation therapy (ADT). ADT…
This post was originally published on this site Transbronchial lung cryobiopsy — a relatively new method of collecting lung tissue for analysis — safely and successfully helps to provide a definitive sarcoidosis diagnosis when the usual and less-invasive diagnostic tools are insufficient, a Portuguese study suggests. The study, “Diagnostic yield and safety of transbronchial cryobiopsy…
This post was originally published on this site Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial assessing the safety and efficacy of its investigational agent NKTR-255 in people with relapsed or refractory non-Hodgkin’s lymphoma and multiple myeloma. The study (NCT04136756) is recruiting up to 82 patients across multiple U.S. sites and also will…
This post was originally published on this site Efforts are underway this month to focus attention on Alzheimer’s (AD), a disease that, along with other forms of dementia, affects some 44 million people globally and is rapidly growing in prevalence. During November in the U.S., Alzheimer’s Awareness Month observances include online tributes to caregivers, listings of…
This post was originally published on this site Oligomannate (GV-971), a compound derived from marine brown algae that promotes a healthy gut microbiome, is now conditionally approved in China to treat mild to moderate Alzheimer’s disease (AD), making it the first new disease therapy approved anywhere since Allergan’s Namenda (memantine) in late 2003. The decision was…
This post was originally published on this site OTL38, a tumor-specific fluorescent compound that “lights up” ovarian tumor tissue during surgery, helped doctors to detect and remove cancer cells that would otherwise be missed, final results of a Phase 2 study show. The study, “A phase II, multicenter, open-label trial of OTL38 injection for the…
This post was originally published on this site Health Canada has approved Darzalex (daratumumab), in combination with standard Revlimid (lenalidomide) and dexamethasone, for people newly diagnosed with multiple myeloma who are not eligible for an autologous stem cell transplant. Under priority review, the approval was based on data from the Phase 3 MAIA trial (NCT02252172), in which…
This post was originally published on this site This week, I want to dive into a topic that’s not always at the top of the list during one’s oncology appointments. Yet it’s something that most of us do regularly (or at least we’d like to be) and it’s something that — surprise, surprise — cancer…
This post was originally published on this site A combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) extends overall survival and the time lived without disease progression in people with newly-diagnosed, inoperable hepatocellular carcinoma (HCC), the most common type of liver cancer, compared to standard-of-care treatment with Nexavar (sorafenib), results from the IMbrave150 Phase 3 trial…
This post was originally published on this site Challenging conventional wisdom, new findings suggest that hormone therapy may have a greater impact than chemotherapy on long-term quality of life in women with breast cancer, particularly those who have gone through menopause. The study, “Differential impact of endocrine therapy and chemotherapy on quality of life of…
